Association between kidney measurements and cognitive performance in patients with ischemic stroke

Data source

Using a retrospective design, this study analyzed data from 608 patients aged 60 to 80 years with acute ischemic stroke within 72 hours of onset between January 2016 and December 2020 from inpatient medical records and a database of cognitive assessment results for outpatient visits one month after hospital discharge. Data was collected from September 1, 2019. During or after data collection, investigators had access to information that could identify individual patients. All patients were no history of a cognitive disorder before stroke and were able to complete the assessment, excluding patients who could not cooperate with the examination, such as aphasia or consciousness disorder. The study was conducted at the Department of Neurology, Second Hospital of Shanxi Medical University, Taiyuan, a tertiary hospital in Shanxi, China. This study was approved by the Ethics Committee of the Second Hospital of Shanxi Medical University (NO. 2019YX214). The research was completed in accordance with Helsinki Declaration. Due to the retrospective nature of the study, informed consent of the patients was not required. The data included renal function parameters, such as serum creatinine and UACR, and cognitive function test findings, such as mini-mental status examination (MMSE) and Montreal Cognitive Assessment (MoCA) scores.

Clinical and laboratory data

Clinical data extracted from hospital records on admission, included systolic and diastolic blood pressure on admission, self-reported demographic characteristics (age, gender, height, weight, years of education, smoking and alcohol consumption status, and diabetes mellitus and hypertension history), laboratory results (total cholesterol, triglyceride, homocysteine, uric acid, fasting glucose, urea, creatinine, and UACR). Additionally, data on neural function assessment (National Institutes of Health Stroke Scale [NIHSS] score) were available. All patients were diagnosed as large artery atherosclerosis (LAA), cardioembolism (CE), small artery occlusion (SAO), stroke of other determined cause (SOC), and stroke of undetermined cause (SUC) according to TOAST classification.(25) Body mass index (BMI) was calculated as weight (in kilograms) divided by height (in meters) squared. eGFR was calculated using the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) equation, which is more accurate than the modification of diet in renal disease (MDRD) equation.(26) Where serum creatinine (Scr) is expressed in mg/dL and age in years; κis 0.7 for females and 0.9 for males; α is –0.329 for females and –0.411 for males; min indicates the minimum of Scr/κor 1, and max indicates the maximum of Scr/κor 1.

Cognitive impairment testing

All the cognitive function tests were assessed by two neuropsychological assessors trained in consistency using MMSE and MoCA one month after hospital discharge. The MMSE and MoCA scores ranged from 0 to 30; higher scores indicated better cognitive function. MMSE testing components included 30 point within four dimensions: ten points for orientation, six for registration and memory, five for attention and calculation, and nine for language and visuospatial abilities. MoCA testing domains included visuospatial and executive function (5 points), naming (3 points), memory (5 points), attention (6 points), language/abstraction (5 points) and orientation (6 points).

Statistical analysis

The study was based on analysis of data obtained from a retrospective design. Patient characteristics were presented as means ± standard deviations (SD) for continuous variables, and categorical variables were reported as frequencies and percentages. Differences between groups for continuous data were tested by one-way analysis of variance (ANOVA). Differences between groups for proportions were tested with a Chi-square test. Data on UACR were not normally distributed; therefore, they were log-transformed before analysis. Standard definitions were used to categorize eGFR data into three groups, comprising ≥90 ml/min/1.73 m² as reference, 60–89 ml/min/1.73 m², and <60 ml/min/1.73 m². Thereafter, eGFR was analyzed as a continuous variable (per 5 mL/min/1.73 m² decreased). UACR values were categorized as <30 mg albumin/g creatinine (normal to mildly increased as reference), 30–300 mg/g (moderately increased), and >300 mg/g (severely increased). Multivariate linear regression was used to assess the association between eGFR or UACR and cognitive performance, with eGFR or UACR as the independent variable and MoCA and MMSE scores as the dependent variables. Two models, Models 1 and 2, were used for the regression analysis. Model 1 was crude, and multivariate-adjusted Model 2 was constructed to adjust for potential confounding variables associated with kidney function and/or cognitive function, including age, gender, BMI, education, diabetes and hypertension history, NIHSS score, stroke subtypes, smoking and alcohol consumption status, serum total cholesterol, triglyceride, uric acid, homocysteine, fasting glucose, systolic blood pressure (SBP), and either eGFR or UACR. Crude and adjusted ß with 95% CIs are presented. Two-tailed P <0.05 was considered statistically significant. All analyses were performed using Empower (R)(www.empowerstats.com, X&Y Solutions Inc., Boston, MA) and R (http://www.R-project.org).

Population characteristics

Table 1 shows demographic and laboratory data on all 608 patients. Patients had a mean age of 66.6 years (SD: 4.1 years) and 48% of patients were females. Average eGFR and UACR were 88.4±12.9 ml/min/1.73 m² and 83.6 ± 314.2 mg/g, respectively. Levels of eGFR were >90 ml/min/1.73m² (N=371, 61%), 60–89 ml/min/1.73m² (N=207, 34%), and <60 ml/min/1.73m² (N=30, 5%). The number of patients with UACR<30 mg/g was 338 (56%). Moderately increased UACR, defined as a UACR 30-300mg/g, was present in 240(39%) of patients, and severely increased UACR, defined as a UACR >300 mg/g, was present in 30(5%) of patients.

Patients with lower eGFR categories were more likely to be older and former or current alcohol consumers and smokers. In addition, they were more likely to have diabetes mellitus, and hypertensive disease, and high systolic blood pressure (SBP) and diastolic blood pressure (DBP) on admission. Their homocysteine, blood glucose, uric acid, and total cholesterol levels were more likely to be higher, as well as a higher BMI. The eGFR levels were lower in patients with albuminuria than in normal patients. As compared with patients with UACR <30 mg/g, patients with UACR ≥30 mg/g were more likely to be living with obesity, diabetes mellitus, and hypertensive disease. Additionally, they were more likely to have higher SBP and DBP, blood glucose, uric acid, and homocysteine levels. Patients had lower cognitive scores in the lower eGFR and higher UACR categories (Table 1).

Independent and combined associations between eGFR and UACR levels and cognitive performance

Table 2 contains the results of unadjusted and fully adjusted (age, gender, BMI, education, diabetes and hypertension history, NIHSS score, stroke subtypes, smoking and alcohol consumption status, serum total cholesterol, triglyceride, uric acid, homocysteine, fasting glucose, SBP, and eGFR or UACR) models for continuous and categorical relationships between measures of renal disease and cognitive tests. The correlation between UACR and MMSE and MoCA scores in crude and multivariate adjustment were statistically non-significant. In the crude and adjusted analyses, no independent associations were observed between UACR, as a category, and cognitive performance. Similarly, no independent associations were observed when UACR was analyzed as a continuous variable in Models 1 and 2 (Table 2).

The association between eGFR and the tests of cognitive performance was evaluated with crude and multivariable linear regression analyses. eGFR was analyzed as a categorical (≥90, 60-90, and <60 ml/min/1.73 m²) and a continuous (per 5 ml/min/1.73 m² decrease) variable. In the multivariable adjustment model, for patients with eGFR 60–90 ml/min/1.73 m² compared to patients with eGFR ≥90 ml/min/1.73 m², an association existed between eGFR and MMSE (ß,-0.7; 95%CI, – 1.0 to –0.3) and MoCA (ß,-1.4; 95%CI, –1.7 to –1.0). The association between eGFR <60 ml/min/1.73 m² and cognitive performance was stronger. In the multivariable adjustment model, MMSE and MoCA were (ß,-4.2; 95%CI –5.0,-3.4) and (ß,-5.2; 95%CI –6.1,-4.4), respectively. When examined as a continuous variable (per 5 ml/min/1.73 m² decrease) in crude and fully adjusted models, eGFR decrements were positively associated with lower MMSE and MoCA scores (p<0.001) (Table 2). In all cases, lower levels of eGFR were associated with poorer cognitive performance.

To assess generalizability, a fully adjusted regression model was created for analyzing the subgroups of sex, stroke subtypes, age, SBP, NIHSS, and blood glucose levels. The results were similar in the subgroup analyses. No significant interactions were found among any of the stratified variables (male versus female, large artery versus small vessel occlusion, age, SBP, NIHSS, and blood glucose dichotomized group: higher versus lower) with eGFR or UACR for cognitive testing. (Tables 3 and 4) When combined categories of eGFR (<90 and ≥90 ml/min/1.73 m²) and albuminuria (<30 and ≥30mg/g) were analyzed, the MMSE and MoCA scores were the least in those patients with UACR ≥30 mg/g and eGFR <90 ml/min/1.73 m², compared to those without albuminuria and eGFR level of ≥90 ml/min/1.73 m² in the crude and fully adjusted model (Table 5).

eGFR and cognitive performance

Our results showed that, in the absence or presence of albuminuria, an eGFR <90 ml/min/1.73 m² had an association with worse cognitive performance. However, the presence of albuminuria amplified the relationship. These findings corroborate the findings of prior studies on the association between renal measures and poorer cognitive performance. According to previous reports, this association exists during the early stages of renal dysfunction.(17, 18) The association between renal function and cognitive performance has been paid much attention in recent decades. Wang et al found that both CKD and eGFR were associated with cognitive dysfunction among older patients with hypertension in China.(27) A prospective study demonstrated that kidney dysfunction is associated with a cognitive decline in a community-based population, and this association is independent of albuminuria.(28) Another longitudinal study suggested that a low eGFR was associated with increased risk of dementia. In addition, a faster decrease in eGFR and proteinuria was associated with incidence of cognitive impairment and dementia; this association may be mediated by vascular mechanisms.(20) Additionally, a large population study found that each 10 ml/min/1.73 m² decrease in eGFR<60 ml/min/1.73 m² was independently associated with an increased prevalence of cognitive impairment.(29) The OSACA2 study found that CKD was independently related to incident dementia in patients with vascular risk factors.(23) However, one cochort study from the Oxford Vascular Study (OXVASC) did not find CKD was associated with either pre– or postevent dementia in patients with TIA and stroke.(24) The inconsistent results may be attributable to different study populations and severity of lesion. OXVASC has focused on the relationship between CKD and dementia in the patients with TIA and stroke. Participants in SPRINT were in older community-dwelling adults with cardiovascular disease. OSACA2 was in high-risk patients for the primary and secondary prevention of cardiovascular disease. Another potential reason is different methods of assessment. Many previous studies have used different assessment tools to evaluate cognitive function.

Although the precise pathophysiologic mechanisms that underlie the association between low eGFR and poorer cognitive performance are not known and need further studies for clarity, several factors may help explain the association between low eGFR and cognitive dysfunction. Patients with renal dysfunction have a higher prevalence of cerebrovascular disease (CVD) than the general population. Renal dysfunction may contribute to vascular cognitive impairment through traditional CVD risk factors, including hypertension, diabetes mellitus, dyslipidemia, smoking, and other non-traditional vascular risk factors comprising hyperhomocysteinemia, hyperuricemia, anemia, inflammation, and oxidative stress. Moreover, CKD characterized by the accumulation of uremic toxins, excessive RAS activation, renal anemia, and renal osteopathy, caused by renal dysfunction are possible mechanisms of renal disease involvement in the progression of dementia.(30, 31) Conceptually, low eGFR may lead to the accumulation of neurotoxins or may represent a prolonged exposure to CVD or its risk factors.(6) Vascular dementia is often linked to hypertension, which is a common finding in CKD. Hypertension has often been associated with small lacunar infarcts and leukoaraiosis, cerebral autoregulation dysfunction, and chronic hypoperfusion. Although cerebral blood flow may be adequate in CKD, the blood–brain barrier or the glymphatic system might be dysfunctional. In this study, more than 50% of the patients had hypertension. Uremic toxins in circulation, which enter the central nervous system (CNS) as a result of blood-brain barrier damage during kidney dysfunction, might impair CNS structure and function.(32)

Albuminuria and cognitive performance

According to recent systematic review and meta-analysis studies, albuminuria has a significant association with cognitive impairment and dementia.(4, 33, 34) To the best of our knowledge, albuminuria is a significant risk factor for the development of dementia in community-based Japanese older adults. Moreover, low eGFR and albuminuria are mutually associated with a greater risk of vascular dementia.(35) A prospective cohort study demonstrated that persistent or progressive albuminuria is associated with cognitive decline in adults with diabetes and normal eGFR.(36) Wei et al found that urine albumin is significantly associated with cognitive dysfunction, and can be potentially used as an early marker for CKD.(37)

The mechanism underlying the association between albuminuria and poorer cognition is not completely understood and is likely multifactorial. Both cerebral and renal circulations have high flow and low impedance. The association between albuminuria and cognitive impairment probably reflects common microvascular pathogenesis in the kidneys and brain. Several reasons may explain the inconsistencies between our findings and those of previous reports. First, the conflicting results may be attributable to use of different study populations in studying the severity of albuminuria. Patients with cognitive dysfunction may reflect in another chronic microvascular disease. This may explain why dementia and poorer cognitive performance are more common in individuals with diabetes who have a high prevalence of albuminuria.(36, 38) However, since fewer patients with diabetes participated in this study (8%), these findings should be interpreted with caution.

The study might be underpowered to detect the association between UACR and poorer cognitive performance. Second, this study only measured UACR at a single time point. UACR is affected by exercise and the time of day the sample is taken,(39) which is why repeated measurements would be preferred. The true association between albuminuria and cognitive performance is likely to be diluted. An alternative explanation for the disparate results of the association between low eGFR and albuminuria and poorer cognitive performance could be that albuminuria is a marker for a different condition other than kidney disease.(40)

This study had several strengths. First, the primary independent and dependent variables were quantified using clinically relevant measures (eGFR and UACR for two independent markers of renal function and damage and MoCA and MMSE for cognitive performance), thus providing clinical relevance to the analyses. In addition, the use of both eGFR and UACR as correlators enabled us to test their independent and joint effects on cognitive performance. Second, the study controlled for several potential confounders, including demographic and clinical parameters, while assessing the association.

Several limitations were noted. First, our study population contained a small number of partients with CKD (eGFR <60 ml/min/1.73 m²), which limited our ability to detect a relationship between eGFR <60 ml/min/1.73 m² and cognitive performance.

Second, these parameters were based on a one-time evaluation and do not provide information on the duration or severity of risk factors over time. Third, we did not analyze impairment in specific cognitive domains; instead, overall cognitive scores were used in the analysis. Finally, the cognitive assessment was performed one month after hospital discharge, and the incidence of post-stroke cognitive impairment is highest three months after stroke.(41) Further long-term follow-up is still needed.

Our findings support the hypothesis that renal dysfunction and albuminuria may operate through different pathophysiologic mechanisms. They further suggest that the pathways mediating the association between low eGFR and albuminuria and poorer cognitive performance may be partially distinct. The findings have clinical implications. Our results suggest that the measurement of eGFR is a good biomarker for cognitive impairment in patients with acute ischemic stroke. Low eGFR may reflect a partially distinct pathophysiologic process of cognitive dysfunction. Targeting the pathogenesis of low eGFR or treating modifiable risk factors may have clinical implications in preventing cognitive impairment or delaying disease progression. Further studies are needed to confirm whether the setting of kidney dysfunction is a possible new determinant for cognitive impairment in patients with stroke.